151 related articles for article (PubMed ID: 31571407)
1. ABCB1 polymorphism predicts the toxicity and clinical outcome of lung cancer patients with taxane-based chemotherapy.
Zhong J; Guo Z; Fan L; Zhao X; Zhao B; Cao Z; Cheng L; Shi Y; Li X; Zhang Y; An T; Wu M; Wang Y; Zhuo M; Li J; Yang X; Chen H; Jia B; Zhao J
Thorac Cancer; 2019 Nov; 10(11):2088-2095. PubMed ID: 31571407
[TBL] [Abstract][Full Text] [Related]
2. Retrospective analysis of second-line chemotherapy outcomes with paclitaxel or docetaxel in correlation with STMN1 polymorphism in advanced non-small cell lung cancer patients.
Powrózek T; Mlak R; Krawczyk P; Bartoń S; Biernacka B; Małecka-Massalska T; Milanowski J
Clin Transl Oncol; 2016 Jan; 18(1):33-9. PubMed ID: 26148901
[TBL] [Abstract][Full Text] [Related]
3. Inherited variation in the ATP-binding cassette transporter ABCB1 and survival after chemotherapy for stage III-IV lung cancer.
Weissfeld JL; Diergaarde B; Nukui T; Buch S; Pennathur A; Socinski MA; Siegfried JM; Romkes M
J Thorac Oncol; 2014 Sep; 9(9):1264-71. PubMed ID: 25122423
[TBL] [Abstract][Full Text] [Related]
4. Impact of ABCB1, ABCC1, ABCC2, and ABCG2 variants in predicting prognosis and clinical outcomes of north Indian lung cancer patients undergoing platinum-based doublet chemotherapy.
Sharma P; Singh N; Sharma S
J Gene Med; 2023 Jan; 25(1):e3460. PubMed ID: 36314103
[TBL] [Abstract][Full Text] [Related]
5. Genetic variation in platinating agent and taxane pathway genes as predictors of outcome and toxicity in advanced non-small-cell lung cancer.
Lamba JK; Fridley BL; Ghosh TM; Yu Q; Mehta G; Gupta P
Pharmacogenomics; 2014; 15(12):1565-74. PubMed ID: 25340731
[TBL] [Abstract][Full Text] [Related]
6. Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer.
Han JY; Lim HS; Yoo YK; Shin ES; Park YH; Lee SY; Lee JE; Lee DH; Kim HT; Lee JS
Cancer; 2007 Jul; 110(1):138-47. PubMed ID: 17534875
[TBL] [Abstract][Full Text] [Related]
7. ABCB1 c.3435C>T polymorphism is associated with platinum toxicity: a preliminary study.
De Troia B; Dalu D; Filipazzi V; Isabella L; Tosca N; Ferrario S; Gambaro AR; Somma L; Fasola C; Cheli S; Clementi E; De Francesco D; Falvella FS; Cattaneo MT
Cancer Chemother Pharmacol; 2019 Apr; 83(4):803-808. PubMed ID: 30796464
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenetic predictors of toxicity to platinum based chemotherapy in non-small cell lung cancer patients.
Pérez-Ramírez C; Cañadas-Garre M; Alnatsha A; Villar E; Delgado JR; Faus-Dáder MJ; Calleja-Hernández MŸ
Pharmacol Res; 2016 Sep; 111():877-884. PubMed ID: 27498158
[TBL] [Abstract][Full Text] [Related]
9. Predictive value of ABCB1 polymorphisms G2677T/A, C3435T, and their haplotype in small cell lung cancer patients treated with chemotherapy.
Knez L; Košnik M; Ovčariček T; Sadikov A; Sodja E; Kern I; Cufer T
J Cancer Res Clin Oncol; 2012 Sep; 138(9):1551-60. PubMed ID: 22543673
[TBL] [Abstract][Full Text] [Related]
10. Subsequent chemotherapy improves survival outcome in advanced non-small-cell lung cancer with acquired tyrosine kinase inhibitor resistance.
Kuo CH; Lin SM; Lee KY; Chung FT; Hsieh MH; Fang YF; Yu CT; Kuo HP
Clin Lung Cancer; 2010 Jan; 11(1):51-6. PubMed ID: 20085868
[TBL] [Abstract][Full Text] [Related]
11. Long progression-free survival with first-line paclitaxel plus platinum is associated with improved response and progression-free survival with second-line docetaxel in advanced non-small-cell lung cancer.
Macedo-Pérez EO; Morales-Oyarvide V; Mendoza-García VO; Dorantes-Gallareta Y; Flores-Estrada D; Arrieta O
Cancer Chemother Pharmacol; 2014 Oct; 74(4):681-90. PubMed ID: 25059320
[TBL] [Abstract][Full Text] [Related]
12. ATP-binding cassette B1 gene polymorphisms, mRNA expression and chemosensitivity to paclitaxel in non-small cell lung cancer cells.
Meng X; Wang G; Liu P; Hou J; Jin Y; Yu Y; Bai J; Chen F; Sun W; Fu S
Respirology; 2011 Nov; 16(8):1228-34. PubMed ID: 21883677
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors in non-small cell lung cancer patients who are recommended to receive single-agent chemotherapy (docetaxel or pemetrexed) as a second- or third-line chemotherapy: in the era of oncogenic drivers and molecular-targeted agents.
Shukuya T; Ko R; Mori K; Kato M; Yagishita S; Kanemaru R; Honma Y; Shibayama R; Koyama R; Shimada N; Takahashi K
Cancer Chemother Pharmacol; 2015 Oct; 76(4):771-6. PubMed ID: 26259641
[TBL] [Abstract][Full Text] [Related]
14. Cytochrome P450 1B1 (CYP1B1) polymorphisms are associated with clinical outcome of docetaxel in non-small cell lung cancer (NSCLC) patients.
Vasile E; Tibaldi C; Leon GL; D'Incecco A; Giovannetti E
J Cancer Res Clin Oncol; 2015 Jul; 141(7):1189-94. PubMed ID: 25504507
[TBL] [Abstract][Full Text] [Related]
15. Polymorphisms of Genes Encoding Multidrug Resistance Proteins as a Predictive Factor for Second-Line Docetaxel Therapy in Advanced Non-small Cell Lung Cancer.
Szczyrek M; Mlak R; Krawczyk P; Wojas-Krawczyk K; Powrózek T; Szudy-Szczyrek A; Zwolak A; Daniluk J; Milanowski J
Pathol Oncol Res; 2017 Jul; 23(3):607-614. PubMed ID: 27988838
[TBL] [Abstract][Full Text] [Related]
16. Effect of ABCB1 C3435T polymorphism on docetaxel pharmacokinetics according to menopausal status in breast cancer patients.
Fajac A; Gligorov J; Rezai K; Lévy P; Lévy E; Selle F; Beerblock K; Avenin D; Saintigny P; Hugonin S; Bernaudin JF; Lokiec F
Br J Cancer; 2010 Aug; 103(4):560-6. PubMed ID: 20628376
[TBL] [Abstract][Full Text] [Related]
17. Effects of genetic polymorphisms in the ABCB1 gene on clinical outcomes in patients with gastric cancer treated by second-line chemotherapy.
Shitara K; Matsuo K; Ito S; Sawaki A; Kawai H; Yokota T; Takahari D; Shibata T; Ura T; Ito H; Hosono S; Kawase T; Watanabe M; Tajima K; Yatabe Y; Tanaka H; Muro K
Asian Pac J Cancer Prev; 2010; 11(2):447-52. PubMed ID: 20843132
[TBL] [Abstract][Full Text] [Related]
18. EGFR mutations as a predictive marker of cytotoxic chemotherapy.
Park JH; Lee SH; Keam B; Kim TM; Kim DW; Yang SC; Kim YW; Heo DS
Lung Cancer; 2012 Aug; 77(2):433-7. PubMed ID: 22521649
[TBL] [Abstract][Full Text] [Related]
19. The impact of ABCB1 gene polymorphism and its expression on non-small-cell lung cancer development, progression and therapy - preliminary report.
Zawadzka I; Jeleń A; Pietrzak J; Żebrowska-Nawrocka M; Michalska K; Szmajda-Krygier D; Mirowski M; Łochowski M; Kozak J; Balcerczak E
Sci Rep; 2020 Apr; 10(1):6188. PubMed ID: 32277145
[TBL] [Abstract][Full Text] [Related]
20. [Influence of apatinib and VEGFR2-906T>C polymorphism on clinical outcomes of advanced non-small cell lung cancer patients].
Zhao RH; Zhou YN; Li H; Li R; Zhang WJ; Zong H
Zhonghua Yi Xue Za Zhi; 2019 Jan; 99(2):105-110. PubMed ID: 30669747
[No Abstract] [Full Text] [Related]
[Next] [New Search]